Clinical trials: Endometrial Carcinoma
Cervical Cancer, Endometrial Cancer
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.
- Trial name
- PARCERII (NCT05857631)
- Testing
- Hypofractionated Image guided External Beam Radiation Therapy (EBRT), Cisplatin, Vaginal brachytherapy
- Where
- 2 sites in India
- Volunteers
- 90 people
- Sponsor
- Tata Memorial Centre
High-risk Endometrial Cancer
Predictors of Recurrence for High Risk Endometrial Cancer Patients
This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.
- Trial name
- NCT04412902
- Testing
- adjuvant therapy
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- Far Eastern Memorial Hospital
Endometrial Cancer
Papillary Serous Carcinoma of the Endometrium
Primary Objectives: To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival.
- Trial name
- NCT00515073
- Testing
- Paclitaxel, Pelvic Radiation, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
Overweight and obese endometrial cancer (EC) survivors at the University of North Carolina (UNC) at Chapel Hill will be approached for tailored feedback fitness intervention.
- Trial name
- MOVES (NCT03820024)
- Testing
- Tailored Feedback Messages
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Cancer
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01797523
- Testing
- Metformin, Letrozole, Everolimus
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Endometrial Cancer
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or…
- Trial name
- NCT00022620
- Testing
- paclitaxel
- Where
- 8 sites in Austria, Belgium and 4 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer Squamous Cell, Solid Tumors
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.
- Conditions
- Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
- Trial name
- NCT03065062
- Testing
- Palbociclib, Gedatolisib
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.
- Trial name
- NCT04511026
- Testing
- Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Endometrial Cancer
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
This is a phase 2 study of investigational drug niraparib and TSR-042 in patients with advanced/recurrent endometrial cancer. The purpose of this study is to determine whether blocking a protein called poly (ADP-ribose)…
- Trial name
- NCT03016338
- Testing
- Niraparib, TSR-042
- Where
- 7 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Corpus Uteri, Endometrial Cancer
Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)
The purpose of this study is to determine the amount of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in a patients blood and tumor.
- Trial name
- NCT00250016
- Where
- United States
- Sponsor
- University of New Mexico
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )
1. This is a multi-center clinical study to evaluate dual mTORC1/2 inhibitor (ATG 008) or selective inhibitor of nuclear export compound (ATG-010) in combination with chemotherapy in patients with relapsed or metastatic ovarian…
- Trial name
- PORCH (NCT04998760)
- Testing
- ATG-008, ATG-010
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Qi Zhou
Ovarian Cancer, Endometrial Cancer
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
The purpose of the study is to determine if the combination of Everolimus and Letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or…
- Trial name
- NCT02188550
- Testing
- everolimus and letrozole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sinai Hospital of Baltimore
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Anal Carcinoma, Cervical Carcinoma
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
This study investigates changes in physical measures of pelvic health and patient-reported outcomes of sexual function, intimate relationship, and quality of life over time in women undergoing radiation therapy for pelvic cancer.
- Conditions
- Anal Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Malignant Pelvic Neoplasm
- Trial name
- GEORGIA (NCT04713618)
- Testing
- Pelvic Examination, Survey
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Endometrial Cancer
Disseminated Endometrial Cancer Cells During Sonohysterography
The purpose of study is to: 1) determine critical volume necessary to overcome tubal pressure and result in fluid dissemination and 2) evaluate functional viability of any disseminated tumor cells collected during SHG
- Trial name
- NCT00205023
- Testing
- Sonohysterography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Wisconsin, Madison
Endometrial Cancer
Radiation Therapy in Uterine Cancer: Dosimetry Analysis, Clinical Implication, and Survival Analysis
We wish to study radiation therapy in uterine cancer, focusing on dosimetry analysis, clinical implication, and survival analysis.
- Trial name
- NCT04251676
- Testing
- Observational study
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Neoplasms, Endometrial
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care.
- Trial name
- NCT07286331
- Testing
- Mocertatug rezetecan, Paclitaxel, Doxorubicin
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.